John P. Leonard¹, Marek Trneny², Nathan H. Fowler³, Xiaonan Hong⁴, Jun Zhu⁵, Huilai Zhang⁶, Fritz Offner⁷, Adriana Scheliga⁸, Grzegorz Nowakowski⁹, Antonio Pinto¹⁰, Francesca Re¹¹, Laura Maria Fogliatto¹², Phillip Scheinberg¹³, Ian Flinn¹⁴, Claudia Moreira¹⁵, Myron Czuczman¹⁶, Stacey Kalambakas¹⁶, Pierre Fustier¹⁷, Chengqing Wu¹⁶, John Gribben¹⁸, Koji Izutsu¹⁹ (1.Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States of America, 2.Charles University Hospital, Prague, Czech Republic, 3.The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 4.Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, 5.Beijing Cancer Hospital, Beijing, People's Republic of China, 6.Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China, 7.UZ Gent, Gent, Kingdom of Belgium, 8.INCA Instituto Nacional de Cancer, Rio de Janeiro, Federative Republic of Brazil, 9.Mayo Clinic, Rochester, MN, United States of America, 10.Istituto Nazionale Per Lo Studio E La Cura dei Tumori Fondazione Giovanni Pascale, Napoli, Italian Republic, 11.Azienda Ospedaliero-Universitaria di Parma, Parma, Italian Republic, 12.Hospital de Clinicas de Porto Alegre, Porto Alegre, Federative Republic of Brazil, 13.Division of Hematology, Hospital A Beneficencia Portuguesa, Sao Paulo, Federative Republic of Brazil, 14.SCRI Tennessee Oncology Nashville, Nashville, TN, United States of America, 15.Instituto Portugues de Oncologia do Porto Francisco Gentil Epe, Porto, Portuguese Republic, 16.Celgene Corporation, Summit, NJ, United States of America, 17.Celgene Corporation, Boudry, Swiss Confederation, 18.Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom of Great Britain and Northern Ireland, 19.National Cancer Center Hospital, Tokyo, Japan)

Yasuhito Terui¹, John P. Leonard², Nathan H. Fowler³, Franck Morschhauser⁴, Koji Izutsu⁵, Yosuke Minami⁶, Noriko Fukuhara⁷, Tatsuro Jo⁸, Go Yamamoto⁹, Takayuki Ishikawa¹⁰, Tsutomu Kobayashi¹¹, Toru Kiguchi¹², Hirokazu Nagai¹³, Kiyoshi Ando¹⁴, Hisayuki Yokoyama¹⁵, Michiaki Koike¹⁶, Koji Kato¹⁷, Tomoko Ohtsu¹⁸, Stacey Kalambakas¹⁹, Pierre Fustier²⁰, Shuichi Midorikawa¹⁸, Kensei Tobinai⁵ (1.Department of Hematology Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Koto-ku, Japan, 2.Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States of America, 3.Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 4.University of Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associee, Lille, France Metropolitan, 5.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 6.Department of Hematology, National Cancer Center Hospital East, Chiba, Japan, 7.Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 8.Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 9.Department of Hematology, Toranomon Hospital, Tokyo, United States of America, 10.Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan, 11.Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 12.Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan, 13.Department of Hematology and Oncology Research, Nagoya Medical Center, Clinical Research Center, Nagoya, Japan, 14.Department of Hematology and Oncology, Tokai University School of Medicine, Tokyo, Japan, 15.Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan, 16.Department of Hematology, Juntendo University Shizuoka Hospital, Tokyo, Japan, 17.Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka City, Japan, 18.Celgene K.K., Tokyo, Japan, 19.Celgene Corporation, Summit, NJ, United States of America, 20.Celgene Corporation, Boudry, Swiss Confederation)

丸山 大¹, 福原 規子², 伊豆津 宏二^1,3, 内田 俊樹⁴, 楠本 茂⁵, 黒田 純也⁶, 入山 智沙子⁷, 柳田 正光⁷, 塚本 憲史⁸, 末廣 陽子⁹, 南 博信¹⁰, 永井 宏和¹¹, 増田 茂夫¹², 飛内 賢正¹ (1.国立がん研究センター中央病院血液腫瘍科, 2.東北大学病院血液免疫科, 3.虎の門病院血液内科, 4.名古屋第二赤十字病院血液・腫瘍内科, 5.名古屋市立大学病院血液・腫瘍内科, 6.京都府立医科大学病院血液内科, 7.愛知県がんセンター中央病院血液細胞療法部, 8.群馬大学病院血液内科, 9.九州がんセンター血液内科, 10.神戸大学病院腫瘍・血液内科, 11.名古屋医療センター血液内科, 12.バイエル薬品)

加藤 光次¹, 伊豆津 宏二^2,3, 清井 仁⁴ (1.九州大学病院 血液・腫瘍・心血管内科, 2.国立がん研究センター中央病院 血液腫瘍科, 3.虎の門病院 血液内科, 4.名古屋大学 血液・腫瘍内科学)

Michinori Ogura¹, Juan Manuel Sancho², Seok-Goo Cho³, Hideyuki Nakazawa⁴, Junji Suzumiya⁵, Gayane Tumyan⁶, Jin Seok Kim⁷, Anne Lennard⁸, Jose M. Mariz⁹, Nikolai Ilyin¹⁰, Wojciech Jurczak¹¹, Aurelio Lopez Martinez¹², Olga Samoilova¹³, Edvard Zhavrid¹⁴, Eduardo Yanez Ruiz¹⁵, Marek Trneny¹⁶, Leslie Popplewell¹⁷, Christian Buske¹⁸, Won Seog Kim¹⁹, SangJoon Lee²⁰, YunJu Bae²⁰, JeongAh Park²⁰, YeonMi Lee²⁰, SangEun Han²⁰, Larry W. Kwak²¹ (1.Department of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Aichi, Japan, 2.Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 3.Department of Hematology, Leukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 4.Department of Hematology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan, 5.Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, Izumo, Shimane, Japan, 6.Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Moscow, Russian Federation, 7.Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea, 8.Northern Institute for Cancer Care, Newcastle University, Newcastle upon Tyne, Tyne-Wear, United Kingdom of Great Britain and Northern Ireland, 9.Department of Hematology, Instituto Potugues de Oncologia, Porto, Portuguese Republic, 10.Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, St. Petersburg, Russian Federation, 11.Department of Haematology, Jagiellonian University, Krakow, Malopolskie, Republic of Poland, 12.Hospital Arnau de Vilanova, Valencia, Comunidad Valenciana, Spain, 13.Nizhny Novogorod Regional Clinical Hospital, Nizhniy Novgorod, Nizhniy Novgorod region, Russian Federation, 14.N N Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Minsk, Republic of Belarus, 15.Universidad de la Frontera, Temuco, Cautin, Republic of Chile, 16.First Department of Medicine - Department of Hematology, General University Hospital and Charles University in Prague, Prague, Czech Republic, 17.City of Hope, Duarte, Califonia, United States of America, 18.Comprehensive Cancer Center Ulm, Comprehensive Cancer Center Ulm, Ulm, Baden Wurttemberg, Federal Republic of Germany, 19.Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 20.Clinical Development Division, Celltrion, Inc., Incheon, Republic of Korea, 21.Toni Stephenson Lymphoma Center and Department of Hematology and Hematopoietic Cell Transplantation City of Hope, Duarte, Califonia, United States of America)

関口 直宏¹, 内田 俊樹², 和田 信介³, 弘 新太郎³, 福原 慶³, 田島 健太郎⁴, 石澤 賢一⁵ (1.国立病院機構 災害医療センター 血液内科, 2.名古屋第二赤十字病院 血液・腫瘍内科, 3.ファイザーR&D合同会社, 4.ファイザー株式会社, 5.山形大学大学院 医学系研究科)